Medicare Benefits Schedule - Note PN.7.20

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

Related Items: 73313 73316

• Previous - Note PN.7.18
• Next - Note PN.8.1

Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist

Applicable once per patient per episode of disease or per relapse

Fee: $3,000.00 Benefit: 75% = $2,250.00 85% = $2,901.30

(See para PN.7.20 of explanatory notes to this Category)

Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies

Fee: $780.00 Benefit: 75% = $585.00 85% = $681.30

(See para PN.7.20 of explanatory notes to this Category)